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Background: Renal insufficiency (RI) remains as an independent predictor of negative outcomes in most series of patients treated with these 
novel devices. In clinical practice, the diagnostic of RI relies, most of the time, only on the levels of serum creatinine (Cr), which may underestimate 
the real incidence of this disease when compared to creatinine clearance (CrCl). We sought to compare the very long term clinical outcomes of non-
selected patients with RI estimated by the Cr vs. CrCl when treated with PCI with DES.
Methods: Between May 2002 and Jan 2010, 3,320 consecutive patients treated in a single center with DES were divided into 3 groups according 
to their renal function: Group I - Cr <1.5mg/dL and CrCl > 60ml/min (n= 2,714); group II - Cr> 1.5mg/dL (n= 242), and; group III - Cr <1.5mg/dL 
and CrCl < 60ml/min (n= 364). These groups were compared regarding the very long term occurrence of MACE (cardiac death, MI and TLR) and stent 
thrombosis.
Results: Patients allocated to group III were more frequently female (58% vs. 19% in group I and 16.1% in group II, p< 0.001) with low body 
mass index (18.4 vs. 28.5 in group I and 26.8 in group II, p<0.001). Regarding mean age and incidence of DM, HAS, smoking, previous CAD and 
previous stroke, groups II and III were comparable and significantly worse than group I. Patients in groups II and III had also similar angiographic 
characteristics with higher percentage of severe coronary calcification (12.3% and 15% vs. 5.5%, p<0.001) and triple vessel disease (40% and 
34.8% vs. 27.1%, p<0.001) when compared to group I. Clinical FU was achieved in 98.3% of the cases (mean FU time 3.6 years). Survival-free of 
MACE was comparable between groups II and III (80% vs. 85.4, p=0.2) and markedly worse than in group I (88.4%, p=0.02). Of note, patients with 
RI (groups II and III) had higher mortality and MI in their FU. Also, stent thrombosis rates were higher for those patients (2.2% in group II and 1.9% in 
group III vs. 1.4% in group I, p < 0.01).
Conclusions: The use of serum Cr may underestimate the occurrence of RI in up to 60% of the cases. Furthermore, patients with “normal” Cr but 
impaired CrCl have poorer clinical outcomes when compared with those with really normal renal function (CrCl>60ml/min).
